Modern biotechnology used in medicine and pharmaceutical sphere uses methods of influencing the pathological process at the level of molecules and genes. It has two main goals: the analysis of the disease’s pathogenesis at the molecular level and the production of drugs based on genetic modifications of microorganisms and body cells.
The process of decoding the human genome has opened up great opportunities for the development of individual or personalized therapy using substances identical to the body, which can only be produced on the basis of biotechnological processes.
Today, with the advent of biotechnology, we can safely say that modern medicine and pharmacology are on the verge of a revolution. Such a development lies in the fact that the patient, instead of mass therapy, will be able to get personalized therapy modeled on a specific clinical situation. For example, every doctor may prescribe medications available in even online pharmacies like My Canadian Pharmacy – Quality HealthCare produced on the same biotechnological innovative approaches.
Biotechnology, in its current development stage, focuses on diseases for which there are currently no adequate methods of effective therapy. In this case, we are talking about diseases that appear when aging. These include:
- malignant neoplasms;
- arthritis and neurodegenerative diseases (Alzheimer’s and Parkinson’s).
In addition, biotechnology offers effective therapeutic solutions in the treatment of:
- multiple sclerosis;
- orphan diseases.
The relevance of the use of biotechnological methods of therapy, for example, in oncology, is shown by static data on the prevalence of malignant neoplasms. So 8.2 million people die annually in the world from various cancer types. The worst thing is that the number of patients is growing at a dramatic pace. According to forecasts of epidemiologists, over the next 20 years, their number will increase by 70%. Despite such prospects, this sector of the pharmaceutical market began its intensive development only with the onset of the new century.
On the background of today’s situation, when the terms of patent protection for many innovative products come to an end, and very few new drugs appear, large pharmaceutical companies are suffering heavy losses in the traditional sector of the chemical-synthetic business. That is why the interest of large pharmaceutical companies in this young sector is growing and today it determines the process of innovative development in the pharmaceutical industry.
According to market experts, the share of biotechnological products in the total volume of the pharmaceutical industry will increase to 30% by 2020. For comparison, in 2010 it was only 18%. The growth in the share of biotechnological drugs is mainly due to the introduction of completely new molecules to the pharmaceutical market. For example, in 2017 in Germany, the share of biotechnological substances from the total number of newly registered products was 37%.
It is obvious that the leaders of the pharmaceutical market are more and more aware of the importance of this market sector for the development of the pharmaceutical industry. They are rapidly expanding their biotechnology business.